Articles
<![CDATA[PERBANDINGAN EFEKTIVITAS MISOPROSTOL DOSIS 50 µg DAN 100 µg TERHADAP KEBERHASILAN KELAHIRAN INDUKSI DI RSU PKU MUHAMMADIYAH YOGYAKARTA ]]>
<![CDATA[Dania, Haafizah]]>;
<![CDATA[Wahyono, Djoko]]>;
<![CDATA[Retnowati, Sulistiari]]>
<![CDATA[ Pharmaciana Vol 4, No 1 (2014): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (83.369 KB)
|
DOI: 10.12928/pharmaciana.v4i1.401
<![CDATA[In recent years, misoprostol that is a prostaglandin E1 analogue has been used in cervix ripeningat pregnancy and labor induction. However, until now misoprostol dosage and administration route forinduction are various. There is no fix guide on administration and dosage of misoprostol. This researchwas intended to identify profile of misoprostol usage and effectiveness of misoprostol administrationat dosage of 50 µg and 100 µg on labor process progress of patient hospitalized in Yogyakarta PKUMuhammadiyah Hospital based on induction success. This research was non experimental research with historical cohort design. Limitation of this method was not all desired data exist in medical recordand capability of physician was not same. Subject was pregnant mothers giving birth with misoprostolinduction process in delivery room in Yogyakarta PKU Muhammadiyah Hospital from 1 January 2009to 31 December 2010. Data was obtained from medical record, which was then analyzed descriptivelyanalytically to identify misoprostol usage profile and effectiveness of misoprostol tablet administrationat 50 µg and 100 µg dosage on labor process progress. Research subjects who meet the inclusioncriteria in this research was 109 mothers, where 69 women (63,30%) got 50 µg misoprostol and 40women (36,70%) got 100 µg misoprostol. The results of this study indicate that the success ofinduction at 50 ug misoprostol group decreased by 89% compared with 100 ug misoprostol group (RR= 0.11), where the success of 50 ug misoprostol induction for 56 people from 69 people (81.16%),while the success induction at 100 ug misoprostol group as many as 39 people from 40 people(97.50%). The difference was statistically significant with p = 0.014 (p <0.05).]]>
<![CDATA[Evaluasi terapi erytropoetin pada pasien hemodialisa di rumah sakit PKU Muhammadiyah Yogyakarta ]]>
<![CDATA[Adnan, Adnan]]>;
<![CDATA[Dania, Haafizah]]>;
<![CDATA[Supadmi, Woro]]>
<![CDATA[ Pharmaciana Vol 8, No 2 (2018): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (258.863 KB)
|
DOI: 10.12928/pharmaciana.v8i2.7725
<![CDATA[Most of the patients with end-stage renal disease who undergoing hemodialysis received erythropoietin (EPO) therapy for the anemia treatment. Deficiency anemia erythropoietin is a common complication of chronic kidney disease (CKD). EPO therapy is expected to improve the anemia and can improve the quality of life of patients.This study was conducted in an analytic observational with Cross Secsional design. The purpose of this study was to know there was a difference of red blood cell profile involve hemoglobin (Hb), Mean Corpusculair Volume (MCV), Mean Corpusculair Haemoglobin (MCH), Mean Corpusculair Haemoglobin Concentration (MCHC) and quality of life of CKD patients who received EPO and non EPO therapy in PKU Muhammadiyah Yogyakarta Hospital. Inclusion criteria in this study were PGK ICD N18.9 patients who were undergoing hemodialysis therapy at RS PKU Muhammadiyah Yogyakarta, outpatient, can read and understand the questionnaire, and accept to be a respondent.The results of this study showed no significant difference (p>0,05) in red blood cell (Hb, MCV, MCH, MCHC) between EPO and non EPO therapy groups. The associated of EPO with the quality of life of patients in all of KDQOL domains was p> 0.05.The conclusions of this study showed that there was no significant difference between EPO and Non EPO therapy and there was no correlation between EPO and non EPO therapy with quality of life of hemodialysis patients.]]>
<![CDATA[The validation of patient knowledge questionnaire for patients with diabetes mellitus and hyperlipidemia ]]>
<![CDATA[Saputri, Ginanjar Zukhruf]]>;
<![CDATA[Dania, Haafizah]]>;
<![CDATA[Faridah, Imaniar Noor]]>;
<![CDATA[A, Faiza Chusnuni]]>
<![CDATA[ Pharmaciana Vol 8, No 2 (2018): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (290.694 KB)
|
DOI: 10.12928/pharmaciana.v8i2.7508
<![CDATA[Prevalence of Diabetes Mellitus (DM) with Hyperlipidemia increased in Indonesia, where both diseases have a risk of complications towards cardiovascular disease. DM patients with hyperlipidemia require proper management to control blood sugar, total cholesterol and LDL cholesterol. Knowledge is one of the important factors in improving adherence therapy and quality of life of DM-hyperlipidemia patients, especially in controlling blood glucose level and total cholesterol levels. This study aims to develop a patient questionnaire of DM-hyperlipidemia.The study used cross sectional method. Inclusion criteria were patients aged 18 â 70 years old, diagnosed DM-Hyperlipidemia, getting at least 1 oral antidiabetic and oral anti-cholesterol. The questionnaire item of knowledge was developed based on gudeline therapy and previous research reference. Expert validation is done on Doctor who had expert in DM and clinical psychologist. The pilot test was performed on 10 healthy patients and 10 patients of DM-hyperlipidemia who had eligible inclusion criteria. Validation of questionnaire was done on 30 patients of DM-Hyperlipidemia who undergoing therapy at outpatient clinic of PKU Muhammadiyah Hospital Yogyakarta. Data collection was done by interviewing questionnaires in patients. Analysis of data using SPSS with product moment validation test and cronbach alpha to see the reliability of questionnaire.Validation results show there are some invalid items that are in questions 9, 11, 12, 15, 16 and 17, the range of questions about knowledge about hyperlipidemia, medication and general health. Re-validation without invalid item was done and obtained value r> 0.3, with value of Cronbach alpha 0,715.The DM-Hyperlipidemia patient questionnaire was valid and reliable to measure the level of knowledge of DM patients with Dysipidemia.  ]]>
<![CDATA[PERBANDINGAN EFEKTIVITAS MISOPROSTOL DOSIS 50 µg DAN 100 µg TERHADAP KEBERHASILAN KELAHIRAN INDUKSI DI RSU PKU MUHAMMADIYAH YOGYAKARTA ]]>
<![CDATA[Haafizah Dania]]>;
<![CDATA[Djoko Wahyono]]>;
<![CDATA[Sulistiari Retnowati]]>
<![CDATA[ Pharmaciana Vol 4, No 1 (2014): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (83.369 KB)
|
DOI: 10.12928/pharmaciana.v4i1.401
<![CDATA[In recent years, misoprostol that is a prostaglandin E1 analogue has been used in cervix ripeningat pregnancy and labor induction. However, until now misoprostol dosage and administration route forinduction are various. There is no fix guide on administration and dosage of misoprostol. This researchwas intended to identify profile of misoprostol usage and effectiveness of misoprostol administrationat dosage of 50 µg and 100 µg on labor process progress of patient hospitalized in Yogyakarta PKUMuhammadiyah Hospital based on induction success. This research was non experimental research with historical cohort design. Limitation of this method was not all desired data exist in medical recordand capability of physician was not same. Subject was pregnant mothers giving birth with misoprostolinduction process in delivery room in Yogyakarta PKU Muhammadiyah Hospital from 1 January 2009to 31 December 2010. Data was obtained from medical record, which was then analyzed descriptivelyanalytically to identify misoprostol usage profile and effectiveness of misoprostol tablet administrationat 50 µg and 100 µg dosage on labor process progress. Research subjects who meet the inclusioncriteria in this research was 109 mothers, where 69 women (63,30%) got 50 µg misoprostol and 40women (36,70%) got 100 µg misoprostol. The results of this study indicate that the success ofinduction at 50 ug misoprostol group decreased by 89% compared with 100 ug misoprostol group (RR= 0.11), where the success of 50 ug misoprostol induction for 56 people from 69 people (81.16%),while the success induction at 100 ug misoprostol group as many as 39 people from 40 people(97.50%). The difference was statistically significant with p = 0.014 (p <0.05).]]>
<![CDATA[Evaluation of erythropoietin therapy in hemodialysis patients at PKU Muhammadiyah Hospital Yogyakarta ]]>
<![CDATA[Adnan Adnan]]>;
<![CDATA[Haafizah Dania]]>;
<![CDATA[Woro Supadmi]]>
<![CDATA[ Pharmaciana Vol 8, No 2 (2018): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (45.535 KB)
|
DOI: 10.12928/pharmaciana.v8i2.7725
<![CDATA[Most of the patients with end-stage renal disease who undergo hemodialysis receive erythropoietin (EPO) therapy for anemia treatment. Anemia with EPO deficiency is a common complication of chronic kidney disease (CKD). EPO therapy is expected to improve anemia and quality of life of patients. This analytic observational study was conducted in a cross-sectional design. It aimed to identify the difference in red blood cell profiles, namely hemoglobin (Hb), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular Hemoglobin Concentration (MCHC), and quality of life of CKD patients on EPO and non-EPO therapy at PKU Muhammadiyah Hospital in Yogyakarta. The inclusion criteria were PGK ICD N18.9 outpatients who received hemodialysis therapy at this hospital and were literate, able to understand the questionnaire, and willing to be a respondent. The results showed that there was no significant difference (p>0,05) between the red blood cells (Hb, MCV, MCH, MCHC) of the EPO and non-EPO therapy groups. The correlation between the EPO and the quality of life of patients in all of the KDQOL domains was p> 0.05. Aside from the insignificant difference between the EPO and non-EPO therapy groups, the research concluded that there was no correlation between either the EPO or the non-EPO therapy with the quality of life of hemodialysis patients.]]>
<![CDATA[The validation of patient knowledge questionnaire for patients with diabetes mellitus and hyperlipidemia ]]>
<![CDATA[Ginanjar Zukhruf Saputri]]>;
<![CDATA[Haafizah Dania]]>;
<![CDATA[Imaniar Noor Faridah]]>;
<![CDATA[Faiza Chusnuni A]]>
<![CDATA[ Pharmaciana Vol 8, No 2 (2018): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (290.694 KB)
|
DOI: 10.12928/pharmaciana.v8i2.7508
<![CDATA[Prevalence of Diabetes Mellitus (DM) with Hyperlipidemia increased in Indonesia, where both diseases have a risk of complications towards cardiovascular disease. DM patients with hyperlipidemia require proper management to control blood sugar, total cholesterol and LDL cholesterol. Knowledge is one of the important factors in improving adherence therapy and quality of life of DM-hyperlipidemia patients, especially in controlling blood glucose level and total cholesterol levels. This study aims to develop a patient questionnaire of DM-hyperlipidemia.The study used cross sectional method. Inclusion criteria were patients aged 18 – 70 years old, diagnosed DM-Hyperlipidemia, getting at least 1 oral antidiabetic and oral anti-cholesterol. The questionnaire item of knowledge was developed based on gudeline therapy and previous research reference. Expert validation is done on Doctor who had expert in DM and clinical psychologist. The pilot test was performed on 10 healthy patients and 10 patients of DM-hyperlipidemia who had eligible inclusion criteria. Validation of questionnaire was done on 30 patients of DM-Hyperlipidemia who undergoing therapy at outpatient clinic of PKU Muhammadiyah Hospital Yogyakarta. Data collection was done by interviewing questionnaires in patients. Analysis of data using SPSS with product moment validation test and cronbach alpha to see the reliability of questionnaire.Validation results show there are some invalid items that are in questions 9, 11, 12, 15, 16 and 17, the range of questions about knowledge about hyperlipidemia, medication and general health. Re-validation without invalid item was done and obtained value r> 0.3, with value of Cronbach alpha 0,715.The DM-Hyperlipidemia patient questionnaire was valid and reliable to measure the level of knowledge of DM patients with Dysipidemia.  ]]>
<![CDATA[Validity and reliability of the world health organisation-five well being index (WHO-5) questionnaire in early detection of depression during Covid-19 pandemic in Yogyakarta ]]>
<![CDATA[Mutmainnah Siradjuddin]]>;
<![CDATA[Dyah Aryani Perwitasari]]>;
<![CDATA[Lalu Muhammad Irham]]>;
<![CDATA[Haafizah Dania]]>;
<![CDATA[Tetie Herlina]]>
<![CDATA[ Pharmaciana Vol 13, No 2 (2023): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.12928/pharmaciana.v13i2.24319
<![CDATA[The Covid-19 pandemic in Indonesia, including Yogyakarta, has created a psychological impact on the community. One of the psychological impacts is depression. This issue can be overcome by early detecting depression using an instrument called the World Health Organization-Five Well-Being Index (WHO-5). Unfortunately, this instrument is currently unavailable in the Indonesian version. Therefore, this study aims to obtain a valid and reliable Indonesian version of the WHO-5, which can later be used by pharmacists as an instrument to early detect depression in Indonesia, especially in Yogyakarta. This research employed a cross-sectional design. The research subjects were people who visited Apotek UAD 1 and 2, who met the inclusion and were not included in the exclusion criteria. The WHO-5 questionnaire proceeded through a translation process from the English version to the Indonesian version. The original version of the WHO-5 questionnaire, which was the final translated version, was tested on 40 respondents to gain its validity and reliability. The analysis of the validity test using the Pearson Correlation of five questions on the WHO-5 questionnaire has revealed an average value of r = 1, indicating that the questionnaire is valid. The result of the reliability test with Cronbach Alpha is 0.853. In conclusion, the Indonesian version of the WHO-5 questionnaire meets the validity and reliability criteria so that the questionnaire can apply to the community.]]>
<![CDATA[The validation of patient knowledge questionnaire for patients with diabetes mellitus and hyperlipidemia ]]>
<![CDATA[Saputri, Ginanjar Zukhruf]]>;
<![CDATA[Dania, Haafizah]]>;
<![CDATA[Faridah, Imaniar Noor]]>;
<![CDATA[A, Faiza Chusnuni]]>
<![CDATA[ Pharmaciana Vol. 8 No. 2 (2018): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.12928/pharmaciana.v8i2.7508
<![CDATA[Prevalence of Diabetes Mellitus (DM) with Hyperlipidemia increased in Indonesia, where both diseases have a risk of complications towards cardiovascular disease. DM patients with hyperlipidemia require proper management to control blood sugar, total cholesterol and LDL cholesterol. Knowledge is one of the important factors in improving adherence therapy and quality of life of DM-hyperlipidemia patients, especially in controlling blood glucose level and total cholesterol levels. This study aims to develop a patient questionnaire of DM-hyperlipidemia.The study used cross sectional method. Inclusion criteria were patients aged 18 – 70 years old, diagnosed DM-Hyperlipidemia, getting at least 1 oral antidiabetic and oral anti-cholesterol. The questionnaire item of knowledge was developed based on gudeline therapy and previous research reference. Expert validation is done on Doctor who had expert in DM and clinical psychologist. The pilot test was performed on 10 healthy patients and 10 patients of DM-hyperlipidemia who had eligible inclusion criteria. Validation of questionnaire was done on 30 patients of DM-Hyperlipidemia who undergoing therapy at outpatient clinic of PKU Muhammadiyah Hospital Yogyakarta. Data collection was done by interviewing questionnaires in patients. Analysis of data using SPSS with product moment validation test and cronbach alpha to see the reliability of questionnaire.Validation results show there are some invalid items that are in questions 9, 11, 12, 15, 16 and 17, the range of questions about knowledge about hyperlipidemia, medication and general health. Re-validation without invalid item was done and obtained value r> 0.3, with value of Cronbach alpha 0,715.The DM-Hyperlipidemia patient questionnaire was valid and reliable to measure the level of knowledge of DM patients with Dysipidemia.  ]]>
<![CDATA[Evaluation of erythropoietin therapy in hemodialysis patients at PKU Muhammadiyah Hospital Yogyakarta ]]>
<![CDATA[Adnan, Adnan]]>;
<![CDATA[Dania, Haafizah]]>;
<![CDATA[Supadmi, Woro]]>
<![CDATA[ Pharmaciana Vol. 8 No. 2 (2018): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.12928/pharmaciana.v8i2.7725
<![CDATA[Most of the patients with end-stage renal disease who undergo hemodialysis receive erythropoietin (EPO) therapy for anemia treatment. Anemia with EPO deficiency is a common complication of chronic kidney disease (CKD). EPO therapy is expected to improve anemia and quality of life of patients. This analytic observational study was conducted in a cross-sectional design. It aimed to identify the difference in red blood cell profiles, namely hemoglobin (Hb), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular Hemoglobin Concentration (MCHC), and quality of life of CKD patients on EPO and non-EPO therapy at PKU Muhammadiyah Hospital in Yogyakarta. The inclusion criteria were PGK ICD N18.9 outpatients who received hemodialysis therapy at this hospital and were literate, able to understand the questionnaire, and willing to be a respondent. The results showed that there was no significant difference (p>0,05) between the red blood cells (Hb, MCV, MCH, MCHC) of the EPO and non-EPO therapy groups. The correlation between the EPO and the quality of life of patients in all of the KDQOL domains was p> 0.05. Aside from the insignificant difference between the EPO and non-EPO therapy groups, the research concluded that there was no correlation between either the EPO or the non-EPO therapy with the quality of life of hemodialysis patients.]]>
<![CDATA[The quality of life of hemodialysis patients in Yogyakarta, Indonesia ]]>
<![CDATA[Siswandi, Siswandi]]>;
<![CDATA[Perwitasari, Dyah Aryani]]>;
<![CDATA[B Simanjuntak, Lamhot]]>;
<![CDATA[Suhendra, Gugun]]>;
<![CDATA[Wulandari, Dewi]]>;
<![CDATA[Dania, Haafizah]]>;
<![CDATA[Faridah, Imaniar Noor]]>;
<![CDATA[Adnan, Adnan]]>
<![CDATA[ Pharmaciana Vol. 14 No. 1 (2024): Pharmaciana ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.12928/pharmaciana.v14i1.28449
<![CDATA[The assessment of quality of life serves as a critical evaluation of the effectiveness of the administered hemodialysis treatment. The measurement of quality of life can be conducted using the Kidney Disease Quality of Life Short Form (KDQoL-SF™) questionnaire. This research aims to gather information concerning the quality of life among patients with hemodialysis due to chronic kidney failure at the dr. S. Hardjolukito Regional Military Hospital in Yogyakarta. The research employed a cross-sectional design. The respondents consisted of 65 patients selected through purposive sampling based on specific inclusion and exclusion criteria. The Independent T-test, Mann-Whitney test, Chi-Square test and Fischer test were conducted to define the association between quality of life and respondent characteristics. Most of the hemodialysis patients was male (50.8%) with average od age was 54.66 years old. The findings revealed that 64.6% of the respondents experienced moderate/poor quality of life, while 35.4% exhibited good quality of life. Statistical analysis established a significant relationship between respondent characteristics and quality of life based on the variables of age and duration of hemodialysis (p<0.05). Hemoglobin levels, number of prescribed medications, gender, education, occupation and income demonstrated no significant relationship with the quality of life. Among the respondents’ characteristics, age and duration of hemodialysis were associated with the quality of life.]]>
